IQVIA (NYSE:IQV) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a research note released on Saturday,Wall Street Zen reports.

Other equities research analysts have also recently issued reports about the company. HSBC restated a “buy” rating and set a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. TD Cowen increased their price target on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a report on Thursday, July 9th. BMO Capital Markets boosted their price objective on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. lifted their price target on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $243.62.

IQVIA Stock Up 1.9%

Shares of IQV stock opened at $262.09 on Friday. IQVIA has a twelve month low of $154.50 and a twelve month high of $271.80. The stock has a market cap of $43.14 billion, a P/E ratio of 32.52, a P/E/G ratio of 2.24 and a beta of 1.18. The stock has a 50 day moving average of $236.55 and a 200 day moving average of $195.92. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, sell-side analysts expect that IQVIA will post 11.57 EPS for the current year.

Insider Activity

In related news, insider W. Richard Staub sold 5,500 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 15,581 shares of company stock valued at $3,796,021 in the last ninety days. 1.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On IQVIA

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the 4th quarter worth $27,000. Compass Financial Management LLC acquired a new position in shares of IQVIA during the 2nd quarter valued at about $27,000. Gilpin Wealth Management LLC purchased a new stake in shares of IQVIA in the fourth quarter valued at about $27,000. CrossGen Wealth LLC acquired a new stake in IQVIA during the fourth quarter worth about $28,000. Finally, Financial Freedom LLC purchased a new position in IQVIA during the first quarter worth about $25,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.